COPD Drug Discovery: How New Generation Therapies Seek to Target Underlying Disease : Market Research Report

COPD Drug Discovery: How New Generation Therapies Seek to Target Underlying Disease

Published by: Drug and Market Development Publishing

Published: Jun. 1, 2006 - 140 Pages

Chapter 1: Executive Summary

COPD Management

COPD Therapeutics

Pipeline Therapeutics

The COPD Market

Future Perspectives

Chapter 2: COPD Definition and Symptoms

Risk Factors

Epidemiology

Physiological Changes and COPD

Underlying Molecular Mechanisms and COPD

COPD Targets and Therapeutics

Objectives and Scope

Chapter 3: COPD Treatment

Diagnosing COPD

Current COPD Management Approaches

Alternative Therapies and COPD

Global Guidelines

Educational Initiatives

The Media

Chapter 4: COPD Therapeutics

Bronchodilators

Anticholinergics

ß-2 Agonists

Methylxanthines

Corticosteroids

Alpha-1 Antitrypsin Augmentation

Mucolytics

Combination Therapies

Drug Delivery

Chapter 5: Lung Function Characteristic of COPD

Targeting Bronchoconstriction

Emerging Anticholinergics

Emerging ß-2 Agonists

Targeting Inflammation

Targeting Inflammatory Mediators

Targeting Cytokines

Targeting Leukotrienes

Targeting Phosphodiesterases

Targeting Neutrophilic Inflammation

Targeting Infection

Targeting Proteases

Targeting Elastase

Targeting Alpha-1-antitrypsin Deficiency

Targeting Matrix Metalloproteinases

Targeting Signal Transduction

Targeting Oxidants

Targeting Airway Remodeling

Targeting Mucus Hypersecretion

Chapter 6: COPD in the Respiratory Market

Market Size and Key Players

Market Activity

Big Pharma

Small-to Medium-Sized Pharma and Biotech

Diagnostics

Drug Delivery

Key Products

Spiriva®

Serevent® Advair®

Symbicort®

Emerging Players

Market Trends and Opportunities

Chapter 7: Therapeutic and Market Potential of COPD Pipeline Drugs

Therapeutic Potential

Market Potential

Pre-Market Pipeline

COPD Diagnostics and Management

COPD and Education

COPD and Research Needs

COPD and the Patient

Summary

Chapter 8: Expert Interviews

Paolo Baroldi, VP Corporate Drug Development, Chiesi Pharmaceuticals

Dr. Mary Fitzgerald, Executive Vice President (Respiratory), Argenta Discovery

Richard Marsden, Managing Director, Synairgen plc

Kevin Moulder, Domantis, Inc., Vice President, Development

Chapter 9: Company Profiles

ALTANA Pharma AG

Argenta Discovery Ltd

Arriva Pharmaceuticals

AstraZeneca plc

Boehringer Ingelheim GmbH

Chiesi Farmaceutici SpA

DEY L P

Domantis

elbion AG

Epigenesis Pharmaceuticals

Glenmark Pharmaceuticals Ltd

GlaxoSmithKline plc

Sepracor

Synairgen plc

Theravance

Chapter 10: References

Table of Exhibits

Exhibit.2.1. Risk Factors and COPD

Exhibit.2.2. Physiological Changes and COPD

Exhibit.2.3. Immune Components Associated with COPD

Exhibit.2.4. Emerging COPD Target Categories at GSK

Exhibit.3.1. COPD and Asthma Differentiation

Exhibit.3.2. Categorization of Severity of COPD

Exhibit.3.3. Components of COPD Management

Exhibit.3.4. GOLD Objectives

Exhibit.3.5. Additions to GOLD Guidelines(2005)

Exhibit.4.1. Approved Anticholinergics that Address COPD

Exhibit.4.2. ß-2.Agonists Used to Treat COPD

Exhibit.4.3. Inhaled Steroids Used for COPD Treatment

Exhibit.4.4. Combination Therapies Used for COPD Treatment

Exhibit.5.1. Pipeline GSK Compounds that Target Bronchoconstriction

Exhibit.5.2. Emerging Anticholinergics

Exhibit.5.3. Emerging Long-Acting.ß-2 Agonists

Exhibit.5.4. Pipeline PDE4 Inhibitors Indicated for COPD

Exhibit.6.1. Companies Developing Products that Address COPD

Exhibit.6.2. Recent Press Releases from Boehringer for Spiriva®

Exhibit.6.3. Boehringer Products Relevant to COPD

Exhibit.6.4. Revenues from Combination Therapies that Address COPD

Exhibit.7.1. Launched COPD Drugs

Exhibit.7.2. Pharmacology of COPD Pre-Approval Candidates

Exhibit.7.3. Companies with COPD Candidates

Exhibit.7.4. Compounds with Highest Novelty Rating

Exhibit.7.5. EFA Goals Relating to COPD

Abstract

Introduction

Chronic Obstructive Pulmonary Disease (COPD) has been a much neglected area in drug development for several decades but now is the fifth leading cause of death worldwide.

Widely recognized as self-inflicted by smoking, COPD has often had low priority in respiratory programs. It is now realized that at least 600 million people, worldwide, suffer from COPD-numbers indicative of epidemic proportions. Governments, healthcare workers and pharmaceutical companies have recently prioritized and raised awareness of this disease area as one of major unmet medical need. Indicative of prioritization of this disease is the widespread occurrence of COPD-specific drug discovery in respiratory R&D in pharmaceutical companies. It is evident that a paradigm shift is taking place in COPD drug discovery. Rather than the traditional approach of symptom relief; new generation pharmaceuticals are beginning to target underlying disease.

Report Overview

D&MD's COPD Drug Discovery: How New Generation Therapies Seek to Target Underlying Disease market analysis report seeks to provide background information on COPD, relevant drug targets, drug discovery strategies and associated therapeutics in current clinical development. This report examines the major classes of COPD therapeutics and discusses the approved and emerging COPD therapeutics. Buy this report to explore the therapeutic and market potential of select therapeutics and new research data compiled from an up-to-date survey.

Key Reasons to Purchase

Determine what is new in COPD-related drug discovery by review of clinical developments in current pharmaceutical pipelines
Get an up-to-date perspective on wider industry developments related to COPD drug discovery by survey of relevant industry news
Assess the therapeutic potential of emerging COPD therapeutics by understanding underlying drug targets and technology that is facilitated drug development and delivery
Assess the market opportunities associated with COPD drug discovery from maps of the current market landscape, evaluation of market needs and consideration of the direction of early stage drug discovery
Gain broader insight into current COPD treatment by consideration of non-pharmacological approaches
Look inside 20 companies involved in COPD drug discovery, including their product pipelines, financial standing, partnerships & alliances, and more
Obtain a current industry snapshot of COPD drug discovery from a short survey conducted in parallel with the writing of this report
Gain insight into current challenges in COPD drug discovery through in-depth interviews with industry experts

Questions Answered

Who is currently developing COPD therapeutics?
What are the key drug targets that underlie such developments and which have major therapeutic and commercial potential?
How is COPD treatment changing?
What are the relative merits of approved COPD therapeutics?
What are the competitive advantages of new-generation COPD drugs?
Where are the current challenges in COPD drug development?
How can COPD treatment be "tailor-made"
Where are the opportunities relating to COPD drug development?
What are the future prospects for COPD therapeutics?

Market Opportunities

Invest in basic research to uncover the molecular pathways associated with development of COPD and to uncover new drug targets
Develop model systems for clinical investigation of COPD to accelerate drug development
Develop technology platforms for development of targeted COPD therapeutics with reduced side effects
Develop diagnostic tests for use with new therapies so that treatment regimes can be tailored for a specific patient
Investigate the mechanisms involved in the inflammatory response associated with COPD to allow drug targeting of COPD-specific inflammation
Investigate the mechanisms involved in the COPD-specific immune response associated with COPD to allow drug targeting of the COPD-specific immune response
Develop COPD-specific therapeutics that target the systemic element of the disease

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

advertise with us

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

COPD Drug Discovery: How New Generation Therapies Seek to Target Underlying Disease

Table of Contents

Abstract